- AMAG has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $60.7 million.
- AMAG is up 4.5% today from today's close.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in AMAG with the Ticky from Trade-Ideas. See the FREE profile for AMAG NOW at Trade-Ideas More details on AMAG: AMAG Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that focuses on maternal health, anemia, and cancer supportive care. AMAG has a PE ratio of 6. Currently there are 5 analysts that rate AMAG Pharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold. The average volume for AMAG Pharmaceuticals has been 1.2 million shares per day over the past 30 days. AMAG has a market cap of $1.2 billion and is part of the health care sector and drugs industry. The stock has a beta of 1.28 and a short float of 29.3% with 5.37 days to cover. Shares are down 6.2% year-to-date as of the close of trading on Friday. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE. TheStreetRatings.com Analysis: TheStreet Quant Ratings rates AMAG Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and solid stock price performance. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.